China
Africa
Explore chapters and articles related to this topic
Ceftaroline and Ceftaroline–Avibactam
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
In clinical studies ceftaroline–avibactam was administered i.v. as 600 mg ceftaroline fosamil/600 mg avibactam every 8 hours over 1 hour. A single-dose, open-label study investigating the pharmacokinetic interaction between ceftaroline fosamil and avibactam (administered as single doses of 600 mg) showed no significant difference in systemic exposure when the drugs were administered alone vs. concomitantly (Riccobene et al., 2013). Mean Cmax and half-life were 27.94 vs. 26.88 μg/ml and 2.48 vs. 2.5 hours for ceftaroline and avibactam, respectively. Nearly 60% of the ceftaroline fosamil dose was excreted in the urine as ceftaroline, whereas 87–93% of avibactam administered was excreted in urine as avibactam. In the same study, multiple dose regimens (600/600 mg every 12 hours, 400/400 mg every 8 hours, 900/900 mg every 12 hours, and 600/600 mg every 8 hours) were administered to 46 healthy adults for 10 days to compare pharmacokinetic parameters for ceftaroline and avibactam. The results for the 600/600 mg every -8-hour dosage are reported in Table 32.10.
Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review
Published in Paediatrics and International Child Health, 2018
Shrey Mathur, Aline Fuchs, Julia Bielicki, Johannes Van Den Anker, Mike Sharland
Ceftaroline fosamil is a broadspectrum cephalosporin antibiotic with activity against many bacteria, including S. pneumoniae (both penicillin-non-susceptible and multi-drug-resistant strains) and S. aureus (including methicillin-resistant S. aureus) [23]. In a phase 2/3 study (NCT01530763), 160 paediatric patients hospitalised with CAP received either intravenous ceftaroline fosamil or ceftriaxone in a randomised, active-controlled, observer-blinded clinical trial. The effectiveness of ceftaroline fosamil was similar to that of ceftriaxone, with high clinical cure rates at test of cure in the modified intention-to-treat population (94/107; 88% and 32/36; 89%, respectively). Three documented S. aureus infections were successfully treated in the ceftaroline group, including one caused by methicillin-resistant S. aureus. In the phase 4 study (NCT01669980), the safety and effectiveness of ceftaroline fosamil in children was evaluated in a multi-centre, randomised, observer-blinded, active-controlled trial[24]. Ceftaroline fosamil was compared with intravenous ceftriaxone plus vancomycin in patients aged between 2 months and 17 years with complicated CAP. Clinical response rates in the modified intention-to-treat population were 52% (15/29 patients) in the ceftaroline fosamil group and 67% in the comparator group (6/9); clinical stability at Study Day 4 was 21% (6/29) and 22% (2/9), respectively. Ceftaroline fosamil was well tolerated and the clinical response rates were similar to that of ceftriaxone plus vancomycin.
Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study
Published in Infectious Diseases, 2019
Zarchi E. Sumon, Charles S. Berenson, John A. Sellick, Zackery P. Bulman, Brian T. Tsuji, Kari A. Mergenhagen
Despite its prevalence in the literature, data on the efficacy of antimicrobial therapies for vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus remains scarce [5]. Ceftaroline fosamil is a broad-spectrum beta-lactam antibiotic, approved by the US Food and Drug Administration in 2015 for the treatment of bacterial skin and soft tissue infection by MRSA. There is also literature supporting its use as salvage therapy, alone or in combination with another MRSA-active antimicrobial, for treatment of bacteraemia and endocarditis with strains of vancomycin-intermediate S. aureus as well as for daptomycin-non-susceptible S. aureus [5].
A snapshot survey of antimicrobial susceptibility among respiratory Staphylococcus aureus isolates: focus on ceftaroline
Published in Journal of Chemotherapy, 2020
Débora Schmidt de Oliveira, Eliana Carniel, Leandro Reus Rodrigues Perez
Ceftaroline, the active compound of the pro-drug ceftaroline fosamil, is a broad-spectrum cephalosporin with bactericidal activity against multidrug-resistant gram-positive organisms. Ceftaroline has been approved by the Food and Drug Administration (FDA) for treating acute bacterial skin infection, including those MRSA-associated infections, and community-acquired bacterial pneumonia.3